The riskiest asset class is converging with one of the safest in a first-of-its-kind financial product: A Bitcoin-backed municipal bond. Bloomberg's Elizabeth Rembert joins Scarlet Fu on "Bloomberg Markets" to discuss. (Source: Bloomberg)
The riskiest asset class is converging with one of the safest in a first-of-its-kind financial product: A Bitcoin-backed municipal bond. Bloomberg's Elizabeth Rembert joins Scarlet Fu on "Bloomberg Markets" to discuss. (Source: Bloomberg)
FactoryTh/iStock via Getty Images Freeport-McMoRan ( FCX ) down 0.9% in Thursday's trading as copper and other base metals fell following President Trump's speech that dampened hopes for a near-term de-escalation in the Middle East war. Goldman Sachs initiated coverage of Freeport-McMoRan ( FCX ) with a Buy rating and $70 price target, believing the company offers best-in-class exposure to structu...
FactoryTh/iStock via Getty Images Freeport-McMoRan ( FCX ) down 0.9% in Thursday's trading as copper and other base metals fell following President Trump's speech that dampened hopes for a near-term de-escalation in the Middle East war. Goldman Sachs initiated coverage of Freeport-McMoRan ( FCX ) with a Buy rating and $70 price target, believing the company offers best-in-class exposure to structural deficits in the copper market with supplemental gold exposure, and that both macro and geopolitical tailwinds should continue to support higher long-term commodity prices, resulting in increased profitability. Additionally, Freeport's ( FCX ) production volumes are at an inflection point, Goldman's Nick Cash and Cecilia Tang said, which should compound the company's profitability in a higher price environment; while this view is widely accepted by the market given the Grasberg mine restart and higher copper prices, the analysts believe Freeport's "asset level margin convexity is underappreciated," which should drive further margin expansion. As a result, the analysts expect a significantly improved operating profile that should lead to higher levels of free cash flow generation, which should increase Freeport's ( FCX ) balance sheet flexibility, and given the company's historical capital allocation distribution, should result in increased returns to shareholders while simultaneously allocating significant capital to growth initiatives. More on Freeport-McMoRan Freeport-McMoRan: The Drawdown Is A Gift Freeport-McMoRan: The Profit Surge Has Barely Started (Rating Upgrade) Freeport-McMoRan Presents at 35th BMO Global Metals, Mining & Critical Minerals Conference Transcript
BeOne Medicines AG (NASDAQ:ONC) ranks among the oversold European stocks to buy. On March 16, Jefferies lowered BeOne Medicines AG (NASDAQ:ONC) to Hold from Buy and reduced its price target to $290 from $420. According to analyst Faisal Khurshid, Brukinsa continues to be one of the strongest assets in hematology and is predicted to continue […]
BeOne Medicines AG (NASDAQ:ONC) ranks among the oversold European stocks to buy. On March 16, Jefferies lowered BeOne Medicines AG (NASDAQ:ONC) to Hold from Buy and reduced its price target to $290 from $420. According to analyst Faisal Khurshid, Brukinsa continues to be one of the strongest assets in hematology and is predicted to continue […]
Douglas Rissing/iStock via Getty Images The Federal Reserve Bank of Atlanta’s GDPNow model on Thursday lowered its estimate for first-quarter real gross domestic product growth to 1.6% from 1.9% a day earlier. That's well below the ~3% level seen in the run-up to the start of the Iran war at the end of February. The decline came after the morning’s international trade report from the U.S. Census B...
Douglas Rissing/iStock via Getty Images The Federal Reserve Bank of Atlanta’s GDPNow model on Thursday lowered its estimate for first-quarter real gross domestic product growth to 1.6% from 1.9% a day earlier. That's well below the ~3% level seen in the run-up to the start of the Iran war at the end of February. The decline came after the morning’s international trade report from the U.S. Census Bureau and the U.S. Bureau of Economic Analysis revealed a widening trade deficit that offset gains in domestic investment. The nowcast for the contribution of net exports to Q1 real GDP growth fell sharply, dropping from -0.23 percentage points to -0.76 percentage points. This decline more than countered an increase in the nowcast of Q1 real gross private domestic investment growth, which rose from 4.9% to 6.6%. Personal consumption expenditures growth also ticked down slightly, falling from 1.5% to 1.4% in the latest estimate. The next GDPNow update is scheduled for Tuesday, April 7. Atlanta Fed More on US Dollar Index, Invesco DB USD Bullish ETF, etc. Dollar Index Rally Runs Out Of Steam- UDN Is A Bearish Dollar Index ETF Hope Dashed, Risk Appetites Slashed Ahead Of Long Holiday Weekend For Many Hope Boosts Risk Appetites And Drags The Greenback Lower Dollar heads for strongest month since 2024 as Iran war drives safe-haven demand Dollar edges higher on safe-haven demand amid Middle East tensions: Currency Recap
Apple Inc. turns 50, evolving from a near-bankrupt company in the 1990s to a $3.6 trillion tech giant. According to Wedbush analyst Dan Ives, the next chapter won't focus on hardware but on AI. Ives highlights Apple's unmatched legacy, from the Macintosh to the iPhone, and its edge in controlling the entire tech stack — chips, software, and services — with 2.5 billion iOS devices globally. This ec...
Apple Inc. turns 50, evolving from a near-bankrupt company in the 1990s to a $3.6 trillion tech giant. According to Wedbush analyst Dan Ives, the next chapter won't focus on hardware but on AI. Ives highlights Apple's unmatched legacy, from the Macintosh to the iPhone, and its edge in controlling the entire tech stack — chips, software, and services — with 2.5 billion iOS devices globally. This ecosystem now positions Apple to lead in AI, but it also raises the stakes. WWDC: The AI Moment Apple
Snap (NYSE:SNAP) stock is down 7% on Thursday, heading toward $4.50 after opening at $4.90. That decline lands on the last trading session before Good Friday as the U.S. stock market is closed tomorrow. The move adds fresh pain to what has already been a brutal stretch for Snap’s loyal investors. Alarmingly, SNAP shares are ... Snap Falls 7% as Activist Pressure and Child Safety Scrutiny Compound ...
Snap (NYSE:SNAP) stock is down 7% on Thursday, heading toward $4.50 after opening at $4.90. That decline lands on the last trading session before Good Friday as the U.S. stock market is closed tomorrow. The move adds fresh pain to what has already been a brutal stretch for Snap’s loyal investors. Alarmingly, SNAP shares are ... Snap Falls 7% as Activist Pressure and Child Safety Scrutiny Compound an Already Brutal Year
Oil prices are surging today. WTI, the primary U.S. oil price benchmark, jumped more than 10% to over $110 a barrel. Meanwhile, Brent, the global benchmark price, rallied 6% to more than $107 per barrel. Crude prices are soaring following President Trump's address to the nation on Wednesday night, where he threatened to hit Iran "extremely hard." Here's a look at what energy investors should do ri...
Oil prices are surging today. WTI, the primary U.S. oil price benchmark, jumped more than 10% to over $110 a barrel. Meanwhile, Brent, the global benchmark price, rallied 6% to more than $107 per barrel. Crude prices are soaring following President Trump's address to the nation on Wednesday night, where he threatened to hit Iran "extremely hard." Here's a look at what energy investors should do right now. Image source: Getty Images. Continue reading
mbbirdy/E+ via Getty Images Canaccord Genuity launched its coverage of Tango Therapeutics ( TNGX ) with a Buy recommendation and a $30 target on Thursday, citing upside from three trial readouts the cancer drug developer is expected to announce this year. One of the readouts will follow a topline analysis from a Phase 1/2 trial designed to test the company’s lead asset, vopimetostat, in pancreatic...
mbbirdy/E+ via Getty Images Canaccord Genuity launched its coverage of Tango Therapeutics ( TNGX ) with a Buy recommendation and a $30 target on Thursday, citing upside from three trial readouts the cancer drug developer is expected to announce this year. One of the readouts will follow a topline analysis from a Phase 1/2 trial designed to test the company’s lead asset, vopimetostat, in pancreatic cancer with MTAP deletions in combination with two RAS(ON) inhibitors developed by Revolution Medicines ( RVMD ). “Tango's strategy to combine with Revolution Medicines' KRAS agents in pancreatic cancer gives a meaningful head start vs. its competitors,” analyst John Newman wrote. “The combination will boost efficacy in MTAP-deleted and KRAS-mutated pancreatic cancer over Revolution Medicines’ KRAS-targeted agents alone,” he added. The analyst projects roughly $800M in peak U.S. sales from vopimetostat in MTAP-deleted non-small cell lung cancer, for which another readout from a Phase 1/2 monotherapy trial is anticipated in 2026. “We expect data here during 2026 with a focus on overall response rate and progression-free survival. Tango expects data to be quite mature, providing a meaningful readout for vopimetostat,” Newman argued. More on Tango Therapeutics Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Tango rises after Q4 results, clinical pact with Erasca Seeking Alpha’s Quant Rating on Tango Therapeutics
Munro/iStock via Getty Images The first quarter of 2026 was one of those eventful quarters that feels like two or three unfolded in the same time. While the U.S.-Iran War has been going on for over a month, there were several market narratives before that had made the market somewhat stagnant and fragile before the sell-off. There are several themes I'm still investing in despite their recent pain...
Munro/iStock via Getty Images The first quarter of 2026 was one of those eventful quarters that feels like two or three unfolded in the same time. While the U.S.-Iran War has been going on for over a month, there were several market narratives before that had made the market somewhat stagnant and fragile before the sell-off. There are several themes I'm still investing in despite their recent pain that I believe will rebound in Q2. We're already off the deepest lows, and while there are plenty of reasons to be worried or do a little hedging, I'm a believer that we hit a relative market bottom around late March, around the time I said that, “ It Is Time to Be Greedy .” Data by YCharts The SaaSpocalypse Will End Software-as-a-service ("SaaS") was one of the hot themes of the last decade and took a swift dump following the release of agentic coding tools by major frontier labs like OpenAI ( OPENAI ) and Anthropic ( ANTHRO ) in late January. This led to a massive decline in software services stocks, and to me publishing “ I'm Buying the Software Meltdown, ” where I wrote: The central flaw in the thesis against software stocks and the argument against AI eating software is that AI tools require humans to operate. Agents must be piloted, so to speak, and the firms that hire the best pilots ("prompt engineers"?) are likely to succeed even if the tools lower the barriers to entry. ...are we using our phones more now that there are more apps? Are the new apps gaining any actual market share or attention? The floor being lower for being an app developer means that there are more app developers, but it doesn't say that the long tail is paying off in that regard. The future of software in the AI world is unclear, as the ultimate potential of AI systems is still unclear. However, I don't believe that vibecoder entrepreneurs are going to replace the software sector. It doesn't make sense that AI coding tools will make software firms obsolete by allowing for in-house tools to be m...
The US president couldn’t give a single coherent reason for why this aggressive war of choice must still be prosecuted Donald Trump’s self-congratulatory speech on Iran on Wednesday night was as puzzling as it was divorced from reality. I had hoped he would declare victory and end the war. Some feared he might provide cover for a ground invasion. Instead, he told us in essence to be patient, that ...
The US president couldn’t give a single coherent reason for why this aggressive war of choice must still be prosecuted Donald Trump’s self-congratulatory speech on Iran on Wednesday night was as puzzling as it was divorced from reality. I had hoped he would declare victory and end the war. Some feared he might provide cover for a ground invasion. Instead, he told us in essence to be patient, that he is almost done, but he was utterly unclear about what more there is to accomplish. If there was ever a purpose to the war, it was to curtail Iran’s capacity to develop a nuclear weapon. Trump harped on that goal repeatedly in his speech, noting that he had long vowed that he “would never allow Iran to have a nuclear weapon”. But he didn’t mention that Iran has long agreed to eschew a nuclear weapon. If that is the only goal, this entire war has been pointless. Continue reading...